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DNA methylation markers as a triage test for identiﬁcation of
cervical lesions in a high risk human papillomavirus positive
screening cohort
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1 Department of Gynaecologic Oncology, Cancer Research Centre Groningen, University of Groningen, University Medical Centre Groningen, Groningen,
the Netherlands
2Department of Pathology, Cancer Research Centre Groningen, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands
3Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
Objective triage strategies are required to prevent unnecessary referrals for colposcopy in population-based screening programs using
primary high-risk human papillomavirus (hrHPV) testing. We have identiﬁed several DNA methylation markers with high sensitivity
and speciﬁcity for detection of high-grade cervical intraepithelial neoplasia or worse (CIN2+) in women referred for colposcopy. Our
study assessed diagnostic potential of these methylation markers in a hrHPV-positive screening cohort. All six markers (JAM3,
EPB41L3, C13orf18, ANKRD18CP, ZSCAN1 and SOX1) showed similar association across histology in the hrHPV-positive cohort when
compared to the Dutch cohort (each p > 0.15). Sensitivity for CIN2+ was higher using methylation panel C13orf18/EPB41L3/JAM3
compared to the other 2 panels (80% vs. 60% (ANKRD18CP/C13orf18/JAM3) and 63% (SOX1/ZSCAN1), p = 0.01). For CIN3+ all three
methylation panels showed comparable sensitivity ranging from 68% (13/19) to 95% (18/19). Speciﬁcity of SOX1/ZSCAN1 panel
(84%, 167/200) was considerably higher compared to ANKRD18CP/C13orf18/JAM3 (68%, 136/200, p = 2 × 10−5) and C13orf18/
EPB41L3/JAM3 (66%, 132/200, p = 2 × 10−7). High negative predictive value (NPV) (91–95% and 96–99%) was observed for CIN2+
and CIN3+, for all three methylation panels, while positive predictive value (PPV) varied from 25 to 40% for CIN2+ and 15–27% for
CIN3+. Interestingly, 118/235 samples were negative for all six markers (including 106 controls (89.8%), 6 CIN1 (5.1%), 5 CIN2 (4.2%)
and 1 CIN3 (0.8%)). Methylation results from both independent cohorts were comparable as well as high sensitivity for detection of
cervical cancer and its high-grade precursors in hrHPV-positive population. Our study therefore validates these methylation marker
panels as triage test either in hrHPV-based or abnormal cytology-based screening programs.
Introduction
Population-based screening programs for the early detection of
cervical cancer using cytology have drastically reduced the mor-
tality of cervical cancer.1,2 Yet, the clinical sensitivity and
speciﬁcity of cytology leaves room for improvement.3–5 The
proof of a causal relationship between persistent infection of cer-
vical epithelium with high-risk human papillomavirus (hrHPV)
and cervical cancer6,7 coupled with the development of reliable
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and sensitive tests for the detection of hrHPV have led to new
screening algorithms with higher clinical sensitivity for detection
of cervical cancer and its high-grade precursor lesions.8–10 For
example, implementation of hrHPV triage already resulted in
more accurate referrals for colposcopy compared to repeat cytol-
ogy after 6 months.11,12 Since hrHPV testing increases the
sensitivity for detection of underlying cervical intraepithelial neo-
plasia grade 2 or worse (CIN2+) and provides better protection
against invasive cervical cancer compared to cytology, several
countries/regions recently switched toward primary hrHPV-
based screening programs.5,13 However, due to the lower speciﬁc-
ity of the hrHPV testing compared to cytology, efﬁcient strategies
are needed to avoid unnecessary referral of women without dis-
ease and overtreatment of hrHPV positive women. A subsequent
cytological test would decrease the number of false-positive refer-
rals with approximately 60% after a primary hrHPV-positive test
result.14–20 However, this strategy also has several disadvantages
due to the subjective interpretation by the cytopathologist after
awareness of the patient’s HPV status.14–20 Therefore, objective tri-
age strategies are needed to improve the speciﬁcity and to reduce
unnecessary referrals in hrHPV-based screening programs.
Over the course of several years we sought to develop and vali-
date sensitive and speciﬁc DNA methylation assays in order to
further improve the early detection of cervical cancer.21–26 In
cohorts of women referred to the outpatient clinic with an abnor-
mal cytology result, a combination of speciﬁc methylation markers
as a triage method showed similar sensitivity of ~75% for detec-
tion of CIN2+ compared to hrHPV testing, but better speciﬁcity.
Furthermore, in a subgroup analysis of only hrHPV-positive sam-
ples these combinations of methylation markers showed similar
sensitivity and speciﬁcity to detect CIN2+ compared to the total
group of samples.24,25 Other studies also demonstrated high clini-
cal sensitivity and speciﬁcity for CIN2+ using methylation analysis
as a triage test after hrHPV testing, performing similar or better
than cytology.18,27–29 However, most studies were limited to ana-
lysing clinical specimens obtained from cohorts that were primar-
ily screened with cytology rather than with hrHPV test or
generated from nonresponding women, which both might not
reﬂect well women participating in population-based screening
programs using primary hrHPV testing.
The purpose of the present study was to assess the diag-
nostic potential of our previously established CIN2+ speciﬁc
methylation markers (i.e., sensitivity, speciﬁcity and positive
and negative predictive value (PPV and NPV)) in hrHPV
positive women attending the routine national cervical cancer
screening program with high-coverage in Slovenia. The
diagnostic performance was additionally compared to previ-
ously acquired data from a Dutch cohort, which was primarily
used to validate our methylation markers.25,26
Methods
Population selection
Women selected for our study participated in the “Slovenian
HPV Prevalence Study”, a prospective population-based cohort
study which started in 2009/2010 (13). Women were eligible for
inclusion if they were attending the routine organised Slovenian
national cervical cancer screening program. The exclusion cri-
teria were attendance for a gynaecological examination after an
atypical/abnormal cytology result, history of CIN of any grade
or treatment for cervical disease in the preceding year, hysterec-
tomy, and menstruation or pregnancy at presentation (10). For
the current study, women were eligible if they tested positive in
the Abbott RealTime High Risk HPV assay. A total of
262 women were included; 206 women ≥30 years old were not
diagnosed with CIN2+ neither in the ﬁrst nor in the second
screening round (195 controls and 11 CIN1 cases) and
56 women who had histologically conﬁrmed CIN2+ in the ﬁrst
screening round (38/56 were ≥ 30 years old).9,10 The “Slovenian
HPV Prevalence Study” was conducted in accordance with the
Helsinki Declaration and was approved by the National Medical
Ethics Committee at the Slovenian Ministry of Health.10 Written
standardised informed consent was obtained from all of the
women by the participating gynaecologists, and patient
identities were kept secret from all study participants except the
participating gynaecologists.
The data obtained from the Slovenian cohort (age ≥ 30 years)
were compared to previously acquired data from our Dutch
cytology-based cohort25,26 (unpublished data). This cohort
(n = 278, age ≥ 30 years) comprised of listwise complete meth-
ylation data (i.e., only those samples were included with no
missing values) on cervical scrapings from 48 women without
any cervical abnormality, who were treated for nonmalignant
indications and had no history of abnormal Pap smears (con-
trols), as well as 230 scrapings obtained from women who had
been referred to the outpatient clinic with an abnormal Pap
smear (histology: 32 without CIN (controls), 37 CIN1,
49 CIN2, 66 CIN3 and 46 (microinvasive) cervical cancers).
DNA isolation and bisulphite treatment
DNA was isolated from 1.5 ml aliquots of ThinPrep material that
had been stored at −80 C.10 Cells were pelleted at 20,000 × G for
What’s new?
In cervical cancer screening, HPV testing provides greater sensitivity than cytology, but its lower speciﬁcity leads to some
unnecessary treatment referrals. DNA methylation assays could potentially provide better speciﬁcity for identifying CIN2+ in
women carrying high risk HPV. These authors investigated six previously identiﬁed CIN2+ methylation markers. They tested
three different combinations of markers, and found high levels of sensitivity and speciﬁcity, making these markers potentially
useful as part of a population-based screening program.
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1 min at room temperature and were lysed overnight in a
Tris-buffered (pH = 8) solution with 1% SDS and 0.66 mg/ml
proteinase K at 56 C. DNA was extracted with 2.3 volumes of
phenol:chloroform:isoamylalcohol (25:24:1) and Phase Lock
Heavy tubes (5Prime, Hilden, Germany). DNA was subsequently
precipitated in 0.65 M ammonium acetate, 65% ethanol and
0.035 mg/ml glycogen at −20 C for at least 1 h; centrifuged for
1 h at 20,000 × G at 4 C; washed with 70% ethanol and ﬁnally
reconstituted in TE buffer. Quality of the DNA was routinely
assessed using a multiplex PCR.30 DNA concentrations were
determined with Nanodrop ND-1000 (Thermo Fisher Scientiﬁc,
Waltham, MA, USA). One microgram (or at least 0.5 μg) DNA
was treated with sodium bisulphite as per manufacturer’s instruc-
tions (Zymo Research, Irvine, CA, USA) and eluted to obtain
10 ng/μL. Samples were randomly distributed among DNA isola-
tion batches and were again randomised across multiple bisul-
phite treatments.
Quantitative methylation-speciﬁc PCR
Methylation analysis was performed for six markers
(ANKRD18CP, C13orf18, EPB41L3, JAM3, SOX1 and ZSCAN1)
as described previously,24–26 using ACTB as a methylation-
independent reference [31]. For each sample the methylation
level was assessed in a randomised fashion and blinded from clini-
cal data. Samples were transferred to 384 wells PCR plates using a
robotic liquid handling system (JANUS, Perkin Elmer, Waltham,
MA). Sodium bisulphite conversion of samples was repeated if the
mean quantity of ACTB was below 1 ng per reaction. The relative
level of methylation of the region of interest was determined by the
after calculation: average quantity of the methylated region of inter-
est divided by average quantity of the reference ACTB gene and
multiplied by 10,000.31 For 4 markers (ANKRD18CP, C13orf18,
EPB41L3, and JAM3) a sample was considered methylation positive
when a methylation signal was observed with a Cq below 50 in at
least two of the three reaction wells.24,25 A sample was considered
methylation positive for SOX1 or ZSCAN1 if the methylation level
was above a threshold of 19.1 or 132, respectively.26
We also assessed two marker panels with previously
reported relative high sensitivity and speciﬁcity for CIN2+ in
a population of women with abnormal cytology: panel 1)
ANKRD18CP, C13orf18 and JAM3,25 and panel 2) C13orf18,
EPB41L3 and JAM3.26 In addition, we searched for novel
panels of methylation markers for the most optimal combina-
tion with the highest sensitivity and speciﬁcity using explor-
atory data mining on methylation data obtained from
previous studies, now also allowing thresholds above a certain
methylation level (see Supporting Information File 1 for a
detailed description), which resulted in panel 3) SOX1 and
ZSCAN1. Marker panels labelled sample as positive if at least
one of the markers within the panel was positive.
Statistical analysis
Statistical analyses were performed using R(version 3.3.2).32
The Jonckheere-Terpstra test (using 1,000 permutations33) was
employed as a nonparametric test for trends of methylation
levels across severity of the underlying lesion. Cumulative logit
models from the R package ordinal34 were applied to assess
whether log10-transformed methylation levels of each methyla-
tion marker associated equally well with cervical neoplasia
among cohorts. The Dutch reference data was used both as
pairwise complete as well in order to estimate the methylation
test positivity across histological subgroups with maximal preci-
sion. Asymmetrical beanplots were used to visualise DNA
methylation levels across histology and between study
cohorts.35 Correlations between methylation levels and the age
of the Slovenian women considered as controls (<CIN2) were
assessed with Kendall’s tau. Wilcoxon’s signed-rank test was
used to compare Kendall’s correlation matrices of methylation
markers between the Slovenian and Dutch population. Pear-
son’s Χ2 and Fisher’s exact test were used to examine cross-
tabs. Paired comparisons of test-positivity and of sensitivity
and speciﬁcity were made using the McNemar test.36
Results
DNA methylation in hrHPV-positive Slovenian women
DNA quality control showed that 97% (253/262) of sample
aliquots yielded sufﬁcient amount of high quality DNA to per-
form methylation analysis. Within this cohort of 253 Slovenian
hrHPV-positive women, higher methylation levels were con-
sistently associated with the severity of the underlying lesion
(p < 0.02 for each marker, Fig. 1).
The comparison of the methylation data obtained from the
hrHPV-based Slovenian cohort with the Dutch cytology-based
cohort on samples from women above 30 years (n = 235)
revealed a high similarity of methylation level distributions
across histology and between study populations (Fig. 2). Ordi-
nal regression analysis conﬁrmed the strength of the associa-
tion of DNA methylation levels with the severity of the
underlying lesions in both cohorts (each p > 0.15).
Ageing has been associated with gradual increase of meth-
ylation levels in genomic DNA.37,38 To exclude that differ-
ences in methylation levels during progression of disease are
due to age differences, we have performed the evaluation of
the Slovenian hrHPV-positive control group and showed no
signiﬁcant relationship between the age of control women
(n = 189) and DNA methylation levels (Table 1).
After dichotomisation of the methylation markers into posi-
tive or negative methylation, we observed that methylation posi-
tivity of each marker was positively associated with the severity
of the underlying disease in hrHPV-positive women (Table 2A).
Marker JAM3 was the most signiﬁcant marker with most con-
trols and CIN1 samples negative, while almost all CIN3 and
cancers were positive. Although marker EPB41L3 detected most
of the CIN2+ lesions (25/35), also more controls and CIN1 sam-
ples were positive. Since in several countries population-based
screening starts before the age of 30, we have also analysed
whether the positivity rate in CIN2+ was different in women
below and over 30 years. Only for the markers ANKRD18CP
748 DNA methylation markers as triage test in hrHPV-positive women




















and EPB41L3 lower positive rates were observed in women
below 30 years with CIN2+ compared to women with CIN2+
aged 30 years or more (p < 0.05, Table 2B).
Methylation marker panels for disease classiﬁcation
To gain sensitivity without losing too much speciﬁcity for
detection of CIN2+ or CIN3+, three marker panels were
analysed, namely panel 1) ANKRD18CP/C13orf18/JAM3, panel
2) C13orf18/EPB41L3/JAM3 and panel 3) SOX1/ZSCAN1
(Table 3). Within hrHPV-positive women above 30 years we
observed signiﬁcant differences in the sensitivity and speciﬁcity
between panel 3 (SOX1/ZSCAN1) and the other two marker
panels (both p < 10−4). Panel 1 (ANKRD18CP/C13orf18/JAM3)
performed similarly to panel 2 (C13orf18/EPB41L3/JAM3)
Figure 1. Methylation ratio for the six genes analysed by QMSP in Slovenian hrHPV-positive scrapings obtained from women with normal
cytology (controls), CIN1, CIN2, CIN3 or cancer.
van Leeuwen et al. 749




















(p = 0.12). Further comparisons revealed that the sensitivity
for CIN2+ of panel 2 (C13orf18/EPB41L3/JAM3. p = 0.01),
but not for panel 1 (ANKRD18CP/C13orf18/JAM3, p = 0.65),
was higher compared to panel 3 (SOX1/ZSCAN1). The sensi-
tivity for CIN3+ of panel 3 (SOX1/ZSCAN1) was similar to
the other two marker panels (both p > 0.08). Panel 3 (SOX1/
ZSCAN1) demonstrated higher speciﬁcity for ≤CIN1 as well
as ≤CIN2 compared to the other two panels (both p < 10−4). If
we compare the sensitivity and speciﬁcity assessed on hrHPV
Slovenian cohort to the Dutch women with cytologically abnor-
mal samples, all marker panels showed comparable test positiv-
ity (Table S1). Addition of HPV16 and/or HPV18 status to the
methylation marker panels minimally increased the sensitivity,
but decreased speciﬁcity in all analysed panels (data not shown).
Figure 2. Asymmetric beanplots of methylation level distributions across histology and between study populations [Slovenian scrapings
(n = 235) in blue and previously analysed Dutch scrapings (n = 278) in white]. Small horizontal bars indicate individual samples, large
horizontal bars indicate the geometric mean methylation ratio per group and the dotted line signiﬁes the grand geometric mean. [Color ﬁgure
can be viewed at wileyonlinelibrary.com]
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High negative predictive value (NPV) was observed for
all methylation marker panels for both CIN2+ and CIN3+,
namely 91–95% and 96–99%, respectively (Table 3). In con-
trast, the positive predictive value (PPV) varied from 25 to
40% for CIN2+ and 15–27% for CIN3 + .
Interestingly, 118/235 samples were negative for all six
markers including 106 controls (89.8%), six CIN1 (5.1%), ﬁve
CIN2 (4.2%) and one CIN3 (0.8%), while seven samples were
positive for all methylation markers including one control,
one CIN1, one CIN2, two CIN3 and two cancers.
Discussion
The present study shows that the excellent diagnostic perfor-
mance (sensitivity, speciﬁcity, PPV and NPV) of our previ-
ously identiﬁed CIN2+ speciﬁc methylation marker panels,
validated on a Dutch cytologically abnormal cohort, is highly
similar to its diagnostic performance in a Slovenian
population-based hrHPV-positive screening cohort. Together
with high clinical sensitivity and speciﬁcity this enables the
application of our three methylation panels as triage tests irre-
spective of the primary screening method.
Despite the high similarity in the diagnostic performance
of the three marker panels in both study cohorts, there are
some important differences between the two cohorts. The Slo-
venian cohort consisted of women who attended the national
cervical screening program and tested positive on hrHPV. Of
these, some were considered as controls (no CIN2+ in the ﬁrst
nor in the second round) and some as cases (histologically
conﬁrmed CIN2+). In contrast the Dutch cohort only con-
sisted of women with an abnormal cytology result referred to
the outpatient clinic for colposcopy. Therefore, in our Dutch
cohort hrHPV-positive women with normal cytology are
missing, which challenges the correct determination of speci-
ﬁcity as a triage test in a hrHPV-positive cohort. The Slove-
nian hrHPV-positive cohort offers the possibility to determine
the speciﬁcity of the methylation marker panels in this
respect. However, the Slovenian cohort lacks hrHPV-positive
women with a normal cytology triage test result, while in their
follow-up CIN2+ was diagnosed (i.e., false-negative samples).
Table 1. Correlation of methylation levels with the age of
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However, if these samples were included in the current study,
the sensitivity of the methylation marker panels might even
have been higher. Furthermore, in the Dutch study cohort
much more carcinomas were included compared to the Slove-
nian cohort. The Slovenian cohort probably reﬂects better the
expected number of carcinomas identiﬁed by primary hrHPV
screening with cytology triage testing. Though, these differ-
ences in composition do not inﬂuence the observed similarity
in methylation status between both cohorts.
The diagnostic performance of the methylation marker
panels (highest sensitivity 80% and PPV 40% for CIN2+)
(Table 3), as determined in the Slovenian hrHPV-positive
population, seems noninferior to the expected performance of
the conventional cytology as a triage test (weighted sensitivity
of 80% (range 73.8–93.5%) with a PPV of ~30% for
CIN2+).14–20 Yet, this cannot be evaluated in this cohort as
the number of women is too limited. Therefore, to analyse
methylation triage testing compared to cytology triage large
prospective studies should be performed.
In addition to our methylation markers, other methylation
markers have been reported to be noninferior to cytology as
well.18,27–29 The limitations of cytology as a triage test are:
(i) inherent subjective nature of the test, (ii) inability of high-
throughput testing, (iii) high level of skills required for cytotech-
nicians, (iv) moderate speciﬁcity (weighted mean ~60% (range
49.6–76.8%)) despite its high sensitivity (weighted mean 80%),
(v) time consuming preparation of the cytological slides and
(vi) inability of cytology to be performed on self-collected sam-
ples.39 Same limitations account for triage tests based on immu-
nostaining such as p16/KI67.15,39 A full molecular triage
alternative is expected to alleviate these issues and further
improve cervical cancer screening programs.40 Moreover molec-
ular triage testing can be performed on the same DNA extracted
for hrHPV testing. Beside cytology and methylation analysis,
hrHPV partial genotyping has also been proposed as a triage test
for hrHPV positive women, with HPV16/18 typing already
implemented in the USA referral guidelines.41 However, sensi-
tivity and speciﬁcity of HPV16/18 triage is ~60% and 80% to
detect CIN2+ lesions,39,42 which makes it inferior compared to
our methylation markers panels. In our study, despite the small
number of samples, combining HPV genotyping with the meth-
ylation marker panels the sensitivity minimally increased, but
was, as expected, accompanied with a decrease in speciﬁcity,
resulting in no overall additive effect by combining HPV16/18
genotyping with our methylation marker panels. On the other
hand, one might consider combining these two approaches as
Table 3. Key clinical performance indicators of individual markers and methylation marker panels on Slovenian HPV-positive women (n = 235,
age 30)
CIN2+ versus ≤ CIN1 CIN3+ versus ≤ CIN2
Sens Spec PPV NPV Sens Spec PPV NPV
(95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI)
Individual markers
ANKRD18CP 46% 72% 22% 88% 47% 71% 13% 94%
(29.2–63.1) (65.1–78.0) (13.6–22.8) (82.2–92.7) (25.2–70.5) (64.2–76.7) (6.2–22.9) (88.7–96.9)
C13orf18 23% 96% 47% 88% 32% 95% 35% 94%
(11.0–40.6) (91.4–97.8) (23.9–71.5) (82.3–91.5) (13.6–56.5) (90.8–97.3) (15.3–61.4) (89.8–96.7)
EPB41L3 71% 69% 28% 93% 84% 67% 18% 98%
(53.4–84.8) (61.5–74.8) (19.6–39.2) (87.5–96.5) (59.5–95.8) (59.9–72.8) (11.1–28.1) (93.7–99.5)
JAM3 49% 94% 59% 91% 68% 93% 45% 97%
(31.7–65.7) (89.5–96.7) (39.1–75.9) (86.3–94.6) (43.5–86.4) (88.0–95.6) (27.0–64.0) (93.5–98.8)
SOX1 60% 87% 44% 93% 74% 84% 29% 97%
(42.2–75.6) (80.8–90.8) (29.7–58.7) (87.5–95.7) (48.6–89.9) (78.6–88.7) (17.4–44.3) (93.5–99.0)
ZSCAN1 43% 88% 38% 90% 58% 87% 28% 96%
(26.8–60.5) (82.5–92.0) (23.8–55.3) (84.5–93.5) (34.0–78.9) (81.6–91.1) (15.6–45.1) (91.8–98.1)
Methylation marker panels
ANKRD18CP/C13orf18/JAM3 60% 68% 25% 91% 68% 67% 15% 96%
(42.2–75.6) (57.3–69.9) (16–3-35.5) (84.5–94.6) (43.5–86.4) (59.9–72.8) (8.7–25.1) (91.1–98.4)
C13orf18/EPB41L3/JAM3 80% 66% 29% 95% 95% 64% 19% 99%
(62.5–90.9) (58.9–72.4) (20.6–39.5) (89.5–97.8) (71.9–99.7) (57.1–70.2) (11.8–28.3) (95.5–100.0)
SOX1/ZSCAN1 63% 84% 40% 93% 79% 81% 27% 98%
(44.9–78.0) (77.5–88.2) (27.3–54.1) (87.7–95.9) (53.9–93.0) (75.6–86.3) (16.5–41-2) (94.0–99.3)
Abbreviations: CIN, cervical intraepithelial neoplasia; Sens, sensitivity; Spec, specificity, PPV, positive predictive value; NPV, negative predictive value;
95% C, 95% confidence interval.
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most likely the negative-tested patients will have an extremely
small risk to develop cancer.41,43 Future population-based stud-
ies using primary hrHPV-based screening should include the
comparison of the clinical diagnostic performance of these
methylation marker panels with or without HPV genotyping,
since they exhibit better clinical performance as triage methods
such as cytology and in addition most likely are more
economical.
In hrHPV-positive control women, results of all tested
methylation markers were not related to age. However, we
observed that sensitivity of two methylation markers
(ANKRD18CP and EPB41L3) for detection of CIN2+ was
lower in women younger than 30 years old compared to older
women. This is in line with the studies of Hansel et al.44 and
Luttmer et al,17 in which lower methylation rates were
observed in younger women with CIN2+ lesions. It can be
hypothesised that these women have a shorter time of HPV
infection and therefore lower methylation rates are observed
for speciﬁc genes. In contrast, women above 30 years with
underlying CIN2+ lesion probably have long-term persistent
HPV infection, and higher methylation rates are observed
indicating a more progressive state of the lesion.
Identiﬁcation and treatment of cervical cancer precursors
lead to reduction of cervical cancer incidence.1 CIN lesions
that are completely unmethylated for these markers may lack
the capacity to progress to cancer.38,45,46 This raises the ques-
tion whether CIN lesions with a hypermethylated proﬁle rep-
resent the truly progressive cervical cancer precursors. In
theory, analysis of baseline hrHPV-positive scrapings obtained
from women who eventually progressed to CIN2+ is possible
as the reports on the Slovenian HPV Prevalence Study9,10
describe the detection of additional CIN2+ cases in both the
follow-up period within the ﬁrst screening round and in the
second screening round. This will also allow evaluation of the
long-term negative predictive value of DNA hypermethylation
testing. Prospective follow-up studies should investigate
whether hrHPV-positive CIN0/1 lesions those are either
methylation marker positive or negative show progression to
CIN2+ or not. These studies will allow the prediction of the
risk progression for women diagnosed with CIN, thus reduc-
ing overreferrals and overtreatment.
In order to assess the reliability of the results of the current
study, external validation of our DNA methylation panels by
independent teams is deemed essential. The strengths of our
study are the reproducibility of our previously identiﬁed meth-
ylation markers in an independent cohort, their independence
with age and the high combined sensitivity and speciﬁcity of
these methylation markers for CIN2+ and CIN3+, especially
for panels C13orf18/EPB41L3/JAM3 and SOX1/ZSCAN1.
In conclusion, the high sensitivity and reproducibility of
established methylation markers seem to allow safe implemen-
tation of these biomarker panels in population-based screening
programs for cervical cancer. However, further validation of
methylation markers in external laboratories, analysing associa-
tions between DNA hypermethylation and risk of progression
and randomised trials to compare their diagnostic performance
with cytology triage after primary hrHPV-testing are reckoned
to be the decisive steps in order to justify implementation of
methylation analysis as a safe and valid triage strategy.
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